After Perrigo Company PLC’s withdrawal of its first-to-launch generic to Teva Pharmaceutical Industries Ltd.’s ProAir (albuterol sulphate) led Lupin Limited and Teva to split gains, the Indian company is ramping up capacity of the respiratory drug ahead of a delayed flu season and amid another wave of COVID-19 cases in the US.
Perrigo’s Loss Is Lupin’s Gain
Somerset Site Gets 13 Observations
Having gained from Perrigo’s withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by Q4 as demand is seen rising on account of flu and COVID-19 cases in the US. Meanwhile, FDA observations at its Somerset facility are a dampener
More from Business
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
More from Scrip
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.